Snoonu
icon
icon

عربى

DUSPATALIN 135 MG 50 TABLETS

0 QR

Product Description Duspatalin 135. Mebeverinum hydrochloridum 135 mg - Lactosum - Amylum solani - Polyvidonum - talcum - Magnesii stearas qs pro tabletta una compressa - talcum - Saccharum - Gelatina - Acaciae gummi - Carnauba cera pro tabletta compressa obducta. Posology and method of use: Duspatalin 135. 1 dragee (coated tablet) 3 times a day. In persistent cases, the dosage is increased to 2 dragees (coated tablets) 3 times a day. When the desired effect is achieved, the dose after several weeks of treatment, progressively reduced. Duspatalin 135 is preferably 20 minutes before a meal. This is a medicine, no prolonged use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor. Contraindications: for a Hypersensitivity of the constituents of the drug. The use of antispasmodics such as mebeverine hydrochloride is not recommended in cases of pancreatic cystic fibrosis (one case of perforated duodenal ulcer with generalized peritonitis was reported in a patient with pancreatic cystic fibrosis (or cystic fibrosis) and treated with mebeverine hydrochloride). Special precautions: The absence of atropine-like side Duspatalin may be administered to patients with glaucoma or prostatic hypertrophy. Mebeverine hydrochloride appears both in animals and in the in vitro systems 'porfyrinogeen' to be, which thus should encourage caution in cases of acute porphyria. Pregnancy and lactation: About Duspatalin use during pregnancy and lactation are insufficient data to assess the potential damage. There are so far in animal studies not found evidence of a teratogenic effect. Nevertheless Duspatalin recommended during pregnancy and lactation not prescribe. Duspatalin If administered during the lactation period required will be the latter interrupted. Undesirable effects: Cases of allergic reactions such as pruritus, rash, urticaria and angioedema have been reported. driving and using machines: The effect of Duspatalin on the ability to drive or operate machinery has not been studied. Overdose: On purely theoretical grounds would be an effect of CNS can be expected in overdose. There is no specific antidote known. Gastric lavage and symptomatic treatment are recommended. Interactions: There are no known interactions. Incompatibilities: There are no known incompatibilities.

0 QR

Delivery by Merchant

1:20 PM

Product Description Duspatalin 135. Mebeverinum hydrochloridum 135 mg - Lactosum - Amylum solani - Polyvidonum - talcum - Magnesii stearas qs pro tabletta una compressa - talcum - Saccharum - Gelatina - Acaciae gummi - Carnauba cera pro tabletta compressa obducta. Posology and method of use: Duspatalin 135. 1 dragee (coated tablet) 3 times a day. In persistent cases, the dosage is increased to 2 dragees (coated tablets) 3 times a day. When the desired effect is achieved, the dose after several weeks of treatment, progressively reduced. Duspatalin 135 is preferably 20 minutes before a meal. This is a medicine, no prolonged use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor. Contraindications: for a Hypersensitivity of the constituents of the drug. The use of antispasmodics such as mebeverine hydrochloride is not recommended in cases of pancreatic cystic fibrosis (one case of perforated duodenal ulcer with generalized peritonitis was reported in a patient with pancreatic cystic fibrosis (or cystic fibrosis) and treated with mebeverine hydrochloride). Special precautions: The absence of atropine-like side Duspatalin may be administered to patients with glaucoma or prostatic hypertrophy. Mebeverine hydrochloride appears both in animals and in the in vitro systems 'porfyrinogeen' to be, which thus should encourage caution in cases of acute porphyria. Pregnancy and lactation: About Duspatalin use during pregnancy and lactation are insufficient data to assess the potential damage. There are so far in animal studies not found evidence of a teratogenic effect. Nevertheless Duspatalin recommended during pregnancy and lactation not prescribe. Duspatalin If administered during the lactation period required will be the latter interrupted. Undesirable effects: Cases of allergic reactions such as pruritus, rash, urticaria and angioedema have been reported. driving and using machines: The effect of Duspatalin on the ability to drive or operate machinery has not been studied. Overdose: On purely theoretical grounds would be an effect of CNS can be expected in overdose. There is no specific antidote known. Gastric lavage and symptomatic treatment are recommended. Interactions: There are no known interactions. Incompatibilities: There are no known incompatibilities.